isatin has been researched along with harmine in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Colau, D; Dolusić, E; Frédérick, R; Larrieu, P; Masereel, B; Moineaux, L; Pilotte, L; Pochet, L; Stroobant, V; Van den Eynde, B; Wouters, J | 1 |
Hitge, R; Petzer, A; Petzer, JP | 2 |
3 other study(ies) available for isatin and harmine
Article | Year |
---|---|
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line; Drug Design; Enzyme Inhibitors; Humans; Immunologic Factors; Indoles; Kinetics; Mice; Neoplasms; Structure-Activity Relationship; Tryptophan Oxygenase | 2011 |
Isatoic anhydrides as novel inhibitors of monoamine oxidase.
Topics: Acetylcholinesterase; Amines; Amino Acids; Anhydrides; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Isoforms; Quinolones; Structure-Activity Relationship | 2022 |
The inhibition of monoamine oxidase by 2H-1,4-benzothiazin-3(4H)-ones.
Topics: Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2022 |